These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 36117573)

  • 1. The role of vonoprazan in patients with erosive esophagitis.
    Zhang M; Xiao Y; Chen M
    Therap Adv Gastroenterol; 2022; 15():17562848221122623. PubMed ID: 36117573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials.
    Simadibrata DM; Lesmana E; Fass R
    J Gastroenterol Hepatol; 2024 Jun; 39(6):988-999. PubMed ID: 38353152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis.
    Iwakiri K; Sakurai Y; Shiino M; Okamoto H; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Ashida K
    Therap Adv Gastroenterol; 2017 Jun; 10(6):439-451. PubMed ID: 28567114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.
    Chandan S; Deliwala S; Mohan BP; Ramai D; Dhindsa B; Bapaye J; Kassab LL; Chandan OC; Facciorusso A; Adler DG
    Indian J Gastroenterol; 2023 Aug; 42(4):475-484. PubMed ID: 37418052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review with meta-analysis: Efficacy and safety of potassium-competitive acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis.
    Simadibrata DM; Lesmana E; Pratama MIA; Sugiharta AJ; Winarizal AS; Lee YY; Syam AF
    JGH Open; 2024 Mar; 8(3):e13053. PubMed ID: 38523708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
    Laine L; DeVault K; Katz P; Mitev S; Lowe J; Hunt B; Spechler S
    Gastroenterology; 2023 Jan; 164(1):61-71. PubMed ID: 36228734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potassium-competitive acid blockers and proton-pump inhibitors for healing of erosive esophagitis: a systematic review and network meta-analysis.
    Liu Y; Gao Z; Hou X
    Therap Adv Gastroenterol; 2024; 17():17562848241251567. PubMed ID: 38903448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
    Simadibrata DM; Lesmana E; Fass R
    J Gastroenterol Hepatol; 2024 May; 39(5):796-805. PubMed ID: 38263507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potassium-competitive acid blockers and acid-related disorders.
    Huang KZ; Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2024 Jun; 31(3):107-114. PubMed ID: 38483115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.
    Sugano K
    Therap Adv Gastroenterol; 2018; 11():1756283X17745776. PubMed ID: 29383028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
    Ashida K; Sakurai Y; Hori T; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Iwakiri K
    Aliment Pharmacol Ther; 2016 Jan; 43(2):240-51. PubMed ID: 26559637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis.
    Uemura N; Kinoshita Y; Haruma K; Yao T; Kushima R; Kanoo T
    Clin Exp Gastroenterol; 2018; 11():51-56. PubMed ID: 29416369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
    Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
    World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis.
    Yang S; Deng W; Xie Z; Chen J
    Medicine (Baltimore); 2022 Nov; 101(47):e31807. PubMed ID: 36451489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).
    Otake K; Sakurai Y; Nishida H; Fukui H; Tagawa Y; Yamasaki H; Karashima M; Otsuka K; Inatomi N
    Adv Ther; 2016 Jul; 33(7):1140-57. PubMed ID: 27287852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis.
    Zhuang Q; Chen S; Zhou X; Jia X; Zhang M; Tan N; Chen F; Zhang Z; Hu J; Xiao Y
    Am J Gastroenterol; 2024 May; 119(5):803-813. PubMed ID: 38345252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors.
    Mizuno H; Yamada K; Minouchi K; Kamiyamamoto S; Hinoue Y
    Biomed Rep; 2018 Feb; 8(2):148-155. PubMed ID: 29435273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis.
    Shirai Y; Kawami N; Iwakiri K; Kuwana M
    J Scleroderma Relat Disord; 2022 Feb; 7(1):57-61. PubMed ID: 35386943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations.
    Savarino E; Martinucci I; Furnari M; Romana C; Pellegatta G; Moscatelli A; Bodini G; Marabotto E; Savarino V; de Bortoli N; Blandizzi C
    Expert Opin Drug Metab Toxicol; 2016 Nov; 12(11):1333-1341. PubMed ID: 27428571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: A cost-effectiveness analysis in Japan.
    Habu Y; Hamasaki R; Maruo M; Nakagawa T; Aono Y; Hachimine D
    J Gen Fam Med; 2021 Sep; 22(5):237-245. PubMed ID: 34484992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.